Stem Cell Therapy for Diabetic Peripheral Neuropathy

What This Article Covers

Diabetic peripheral neuropathy (DPN) — nerve damage caused by prolonged high blood sugar, usually affecting the feet and hands — has no cure and limited drug options beyond pain management. Researchers are investigating whether stem cells, delivered by injection into affected limbs, can repair damaged nerves and restore blood flow rather than just mask symptoms. The evidence so far is genuinely encouraging in small studies, but it comes from early-phase trials and animal research, not the large, definitive trials needed to establish the therapy as a standard treatment.

How It's Thought to Work

Stem cells used for DPN — most often mesenchymal stem cells (MSCs) from umbilical cord tissue or a patient's own bone marrow — are injected directly into leg or foot muscle. Researchers believe these cells work in two main ways: they release growth factors that support nerve repair and regeneration, and they promote the formation of new small blood vessels (angiogenesis) that improve circulation to nerve tissue starved of blood flow by diabetes. This dual "repair and resupply" mechanism is different from standard neuropathy drugs, which mainly control pain signals rather than address underlying nerve damage.

What the Evidence Shows

The strongest human evidence to date is a 2024 systematic review and meta-analysis in Stem Cell Research & Therapy, which pooled seven controlled trials totaling roughly 400 patients treated with bone marrow-derived cells or umbilical cord MSCs. The results were genuinely promising: treated patients showed measurable gains in both motor and sensory nerve conduction velocity, improved vibration perception, and better scores on a standard neuropathy severity scale, with only mild, temporary injection-site pain and swelling reported — no serious adverse events.

That signal is backed by a substantial preclinical base. A 2024 meta-analysis of 23 animal studies in Frontiers in Bioengineering and Biotechnology found consistent, large improvements in nerve conduction velocity, nerve fiber density, and blood flow after MSC treatment, along with reduced inflammatory markers — though the same review noted MSCs had only modest effects on blood sugar control itself. A companion animal-studies safety and efficacy review reached similarly favorable conclusions on tolerability.

Clinical research is actively expanding: a Phase 1/2 trial at Wuhan Central Hospital is testing umbilical cord MSCs against standard drug therapy in 42 patients with treatment-resistant DPN, tracking nerve conduction and safety over 96 weeks (ClinicalTrials.gov NCT05507697), and a newer randomized controlled trial is now recruiting to test the approach in moderate-to-severe DPN (ClinicalTrials.gov NCT07183761). None of this evidence, however, comes from large Phase 3 trials, and the existing human studies are small and heterogeneous — real limitations the field openly acknowledges.

Who Might Be a Candidate

Stem cell therapy for DPN is not an approved or routinely available treatment, but the research to date has generally focused on patients such as:

• Adults with type 1 or type 2 diabetes and confirmed peripheral neuropathy, typically in the feet or lower legs
• Patients with moderate to severe symptoms — numbness, tingling, burning pain, or loss of sensation — that have not responded adequately to standard medications
• People without active foot ulcers, uncontrolled infection, or other conditions that would make injections into the limb unsafe
• Those enrolled in a registered clinical trial, rather than seeking treatment at a direct-to-consumer stem cell clinic

Bottom Line

Stem cell therapy for diabetic peripheral neuropathy is one of the more encouraging areas of regenerative research for a condition with few good treatment options — small human trials and a large body of animal data both point toward real improvements in nerve function and blood flow, with a favorable early safety profile. But "encouraging early data" is not the same as "proven treatment": the FDA has not approved any stem cell product for DPN, results come from small and short-term studies, and researchers themselves call for larger, longer, and better-controlled trials before this becomes a mainstream option. Patients interested in this approach should look for registered clinical trials rather than commercial clinics offering unproven injections.